Celyad Oncology S.A.

CYAD.BR · BRU
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-€5,824-€8,448-€40,935-€26,512
Dep. & Amort.€450€794€1,440€1,520
Deferred Tax€0€0€0-€531
Stock-Based Comp.€0€935€1,624€2,172
Change in WC-€177-€1,205-€4,015€1,405
Other Non-Cash-€129-€7,278€13,876-€4,697
Operating Cash Flow-€5,680-€15,202-€28,010-€26,643
Investing Activities
PP&E Inv.-€118-€934-€123-€393
Net Acquisitions€15€0€6,000€0
Inv. Purchases€0€0€0€0
Inv. Sales/Matur.€0€0€1,090€0
Other Inv. Act.€0€1,341€235€267
Investing Cash Flow-€103€407€7,202-€126
Financing Activities
Debt Repay.-€167-€145-€896-€1,136
Stock Issued€0€9,490€0€36,568
Stock Repurch.€0€0-€124€0
Dividends Paid€0€0€0€0
Other Fin. Act.€3,150€10€4,261€4,089
Financing Cash Flow€2,983€9,355€3,241€39,521
Forex Effect-€4-€1-€6€32
Net Chg. in Cash-€2,804-€5,441-€17,573€12,784
Supplemental Information
Beg. Cash€7,004€12,445€30,018€17,234
End Cash€4,200€7,004€12,445€30,018
Free Cash Flow-€5,680-€16,101-€28,133-€27,036
Celyad Oncology S.A. (CYAD.BR) Financial Statements & Key Stats | AlphaPilot